← Eichor
Study identifier: NCT06345079 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Condition: Neuroendocrine Tumors  ·  Sponsor: Australasian Gastro-Intestinal Trials Group

PhasePhase 2
Planned participants78
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not. The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

This description comes directly from the study's public registry record.

Talk to the study team

Julia Kuszewski  ·  +61 02 7208 2725  ·  agitg_stopnet_mailbox@gicancer.org.au

Always discuss trial participation with your own doctor first.

Locations (12)

Royal North Shore HospitalSydney, New South Wales, AustraliaRecruiting
Wollongong HospitalWollongong, New South Wales, AustraliaRecruiting
Royal Brisbane and Womens HospitalBrisbane, Queensland, AustraliaRecruiting
The Queen Elizabeth HospitalAdelaide, South Australia, AustraliaRecruiting
Peter MacCallum Cancer CentreMelbourne, Victoria, AustraliaRecruiting
Fiona Stanley HospitalPerth, Western Australia, AustraliaRecruiting
BC Cancer Agency, Vancouver Cancer CentreVancouver, British Columbia, CanadaRecruiting
London Health Sciences Centre Research Institute (LHSCRI)London, Ontario, CanadaRecruiting
Ottawa Hospital Research InstituteOttawa, Ontario, CanadaRecruiting
Odette Cancer Centre Sunnybrook Health Sciences CentreToronto, Ontario, CanadaRecruiting
Allan Blair Cancer CentreRegina, Saskatchewan, CanadaRecruiting
Saskatoon Cancer CentreSaskatoon, Saskatchewan, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06345079